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Refractory focal epilepsy is a devastating disease for which there is frequently no effective 50 
treatment. Gene therapy represents a promising alternative, but treating epilepsy in this way 51 
involves irreversible changes to brain tissue, so vector design must be carefully optimized to 52 
guarantee safety without compromising efficacy. We set out to develop an epilepsy gene 53 
therapy vector optimized for clinical translation. The gene encoding the voltage-gated 54 
potassium channel Kv1.1, KCNA1, was codon-optimized for human expression and mutated 55 
to accelerate the channels’ recovery from inactivation. For improved safety, this engineered 56 
potassium channel (EKC) gene was packaged into a non-integrating lentiviral vector under 57 
the control of a cell type-specific CAMK2A promoter. In a blinded, randomized, placebo-58 
controlled pre-clinical trial, the EKC lentivector robustly reduced seizure frequency in a male 59 
rat model of focal neocortical epilepsy characterized by discrete spontaneous seizures. 60 
When packaged into an adeno-associated viral vector (AAV2/9), the EKC gene was also 61 
effective at suppressing seizures in a male rat model of temporal lobe epilepsy. This 62 
demonstration of efficacy in a clinically relevant setting, combined with the improved safety 63 
conferred by cell type-specific expression and integration-deficient delivery, identify EKC 64 
gene therapy as ready for clinical translation in the treatment of refractory focal epilepsy. 65 
 66 
 67 
Significance statement 68 
 69 
Pharmacoresistant epilepsy affects up to 0.3% of the population. Although epilepsy surgery 70 
can be effective it is limited by risks to normal brain function. We have developed a gene 71 
therapy that builds on a mechanistic understanding of altered neuronal and circuit excitability 72 
in cortical epilepsy. The potassium channel gene KCNA1 was mutated to bypass post-73 
transcriptional editing, and packaged in a non-integrating lentivector to reduce the risk of 74 
insertional mutagenesis. A randomized, blinded pre-clinical study demonstrated therapeutic 75 
effectiveness in a rodent model of focal neocortical epilepsy. Adeno-associated viral delivery 76 
of the channel to both hippocampi was also effective in a model of temporal lobe epilepsy. 77 





Epilepsy affects over 60 million people worldwide (Ngugi et al., 2010). Even with optimal 81 
treatment approximately 30% remain resistant to pharmacotherapy (Kwan et al., 2011). The 82 
development of new anti-epileptic drugs has had little impact on refractory epilepsy; affected 83 
individuals experience major co-morbidities, social exclusion, and an annual rate of sudden 84 
unexpected death of 0.5-1% (Devinsky, 2011; Hoppe and Elger, 2011). Although surgical 85 
resection of the epileptogenic zone can result in seizure freedom, it is unsuitable for over 86 
90% of patients (Lhatoo et al., 2003). Surgical intervention in focal neocortical epilepsy 87 
(FNE) is further complicated by the high risk of damage to eloquent regions of the cortex 88 
(Schuele and Lüders, 2008).  89 
 90 
Gene therapy is a promising option to treat refractory focal epilepsy (Kullmann et al., 2014), 91 
but major hurdles remain in achieving stable, predictable and safe transgene expression. 92 
Because focal seizures often arise from brain areas close to eloquent cortex, lentiviral 93 
vectors, which lead to rapid, stable and, most importantly, spatially-restricted transgene 94 
expression (Lundberg et al., 2008), are an attractive delivery tool. In addition, their large 95 
packaging capacity allows for a wide choice of promoter-transgene combinations, which can 96 
further increase the specificity of expression. Hitherto, clinical trials with lentivectors for CNS 97 
disorders have mainly used ex-vivo treatment of hematopoietic stem cells (Cartier et al., 98 
2009; Biffi et al., 2013), although a recent trial in Parkinson’s disease (PD) relied on a 99 
lentivector injected directly into the striatum (Palfi et al., 2014). A larger number of trials have 100 
used adeno-associated virus (AAV) vectors to treat CNS and ophthalmic disorders including 101 
PD (Muramatsu et al., 2010; LeWitt et al., 2011; Mittermeyer et al., 2012), spinal muscular 102 
atrophy (Mendell et al., 2017), Canavan disease (Leone et al., 2012), Batten disease 103 
(Worgall et al., 2008), Sanfilippo syndrome type B (Tardieu et al., 2017), Leber's congenital 104 
amaurosis (Maguire et al., 2008) and choroideremia (MacLaren et al., 2014). Although they 105 
have a smaller packaging capacity than lentivectors, AAVs also support stable transgene 106 
expression (up to 15 years in non-human primates (Sehara et al., 2017)), and their ability to 107 
spread further through the brain parenchyma potentially makes them better suited to treat 108 
diffuse seizure foci. 109 
 110 
We have previously shown that lentivector-mediated overexpression of the human voltage-111 
gated potassium channel Kv1.1 (encoded by KCNA1) can suppress pathological high-112 
frequency electrocorticographic (ECoG) activity in a model of FNE induced by tetanus 113 
neurotoxin (TeNT) injection into the rat motor cortex (Wykes et al., 2012). However, in this 114 
model, which mimics an especially pharmacoresistant form of FNE, epilepsia partialis 115 
continua (EPC) (Cockerell et al., 1996), discrete seizures lasting over five seconds are rare 116 
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(see also (Kätzel et al., 2014)), so the effectiveness of potassium channel gene therapy in 117 
more common forms of epilepsy remains to be demonstrated.  118 
 119 
Gene therapy based on overexpression of Kv1.1 requires effective targeting of transgene 120 
expression to excitatory neurons. The strong viral promoter CMV successfully drives KCNA1 121 
overexpression in rat pyramidal neurons (Wykes et al., 2012). However, recent data suggest 122 
that CMV cannot support excitatory neuron-specific expression in non-human primates 123 
(Yaguchi et al., 2013; Lerchner et al., 2014). Furthermore, current clinical guidance for 124 
lentiviral gene therapy seeks to reduce the risk of mutagenesis associated with integration 125 
into the genome (Hacein-Bey-Abina et al., 2003; Baum et al., 2004). 126 
 127 
To bring potassium channel gene therapy closer to the clinic, we have designed a construct 128 
that boosts Kv1.1 expression and reduces its inactivation with an engineered potassium 129 
channel gene (EKC), and improves safety with a cell-type-specific (CAMK2A) promoter. The 130 
construct was packaged into both a non-integrating lentiviral vector and an AAV2/9 vector, 131 
and tested for efficacy in models of FNE and of the commonest type of focal epilepsy, 132 
temporal lobe epilepsy (TLE).  133 
  134 
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Materials and methods 135 
 136 
Molecular biology 137 
Lentiviral and AAV transfer plasmids were constructed using standard subcloning 138 
techniques. KCNA1 was codon optimized for human expression using GeneOptimizer® 139 
software, and synthesized using GeneArt® (Thermo Fisher Scientific). All plasmids were 140 
fully sequenced before use. Sequences are available on request. 141 
 142 
Voltage clamp recordings 143 
Neuro-2a cells were grown in Gibco® Dulbecco’s Modified Eagle Medium (DMEM) + 144 
GlutaMAX™ (Thermo Fisher Scientific) supplemented with 10% heat-inactivated fetal bovine 145 
serum (Thermo Fisher Scientific), 1% penicillin/streptomycin (Thermo Fisher Scientific) and 146 
1% non-essential amino acids (Sigma). Cultures were maintained in logarithmic growth 147 
phase in a humidified 5% CO2 atmosphere at 37 °C. Transfections were performed 148 
according to the manufacturer’s instructions using TurboFect™ transfection reagent (Thermo 149 
Fisher Scientific). Transfected cells were plated onto 13 mm borosilicate glass coverslips 150 
(VWR). Coverslips were placed into the chamber of a BX51WI fixed-stage upright 151 
microscope equipped with UMPLFLN 10× and LUMPLFLN 40× water-immersion objectives 152 
(Olympus). Coverslips were submerged in a static bath of extracellular solution with the 153 
following composition (in mM): 140 NaCl, 4 KCl, 1.8 CaCl2, 2 MgCl2, 10 HEPES (pH 7.35, 154 
osmolarity a301 mOsm/L). Filamented borosilicate glass micropipettes (GC150-F; Warner 155 
Instruments) were pulled to tip resistances between 2.0 and 3.0 MΩ using a P-97 156 
Flaming/Brown micropipette puller (Sutter Instrument Company). Micropipettes were filled 157 
with an intracellular solution of the following composition (in mM): 140 KCl, 10 HEPES, 10 158 
EGTA (pH 7.35, osmolarity a291 mOsm/L). Macroscopic currents were recorded under 159 
voltage clamp using the whole-cell patch clamp configuration. The voltage step protocol 160 
used was as follows: cells were held at a resting potential of −80 mV and currents evoked by 161 
200 ms depolarising steps delivered in 10 mV increments up to +20 mV. A 40 ms 162 
hyperpolarising step to −100 mV was included before returning to baseline. Data were 163 
filtered at 3 kHz and acquired at 10 kHz using WinWCP software (J. Dempster, University of 164 
Strathclyde) and an Axon Multiclamp 700B amplifier (Molecular Devices). Series resistance 165 
compensation was employed throughout, with prediction and correction components 166 
adjusted to 80% and the bandwidth set to 1.2 kHz. Cells with series resistance greater than 167 
10 MΩ were excluded from the analysis. All recordings were made at room temperature (23 168 
– 26 qC). The liquid junction potential, calculated to be +4.1 mV, was left uncorrected. Leak 169 




For analysis, evoked currents were taken as the steady-state current in the last 40 ms of 172 
each voltage step. Baseline holding currents were subtracted before division by cell 173 
capacitance to generate current density values. To calculate normalized conductance, the 174 
current density at each voltage step was divided by the step potential minus the potassium 175 
reversal potential (−91.34 mV). This generates raw conductance values that are corrected 176 
for the variation in K+ driving force which accompanies stepwise changes in membrane 177 
potential. Plots of raw conductance against voltage for each EKC-transfected cell were fit 178 
with individual Boltzmann functions given by the equation: 179 
 180 







where G is the conductance, V the voltage, A1 the initial (minimum) conductance, A2 the final 182 
(maximum) conductance, V0.5 the voltage of half-maximal conductance, and k the slope 183 
factor. Raw conductance values were normalized to A1 and A2 of their own Boltzmann 184 
functions. Normalized conductance was then plotted against voltage for all EKC-transfected 185 
cells and mean values were fitted with a single Boltzmann function. 186 
 187 
Lentiviral synthesis 188 
The Lenti-CMV-KCNA1 vector was identical to that used in (Wykes et al., 2012). For the 189 
Lenti-CaMKII-EKC vector and its Lenti-CaMKII-GFP control, human embryonic kidney 293T 190 
(HEK293T) producer cells were grown in Gibco® DMEM + GlutaMAX™ supplemented with 191 
10% heat-inactivated foetal bovine serum and 1% penicillin/streptomycin. Cultures were 192 
maintained in logarithmic growth phase in a humidified 5% CO2 atmosphere at 37 °C. Cells 193 
were split every 3 – 4 days using 0.05% Trypsin-EDTA (Thermo Fisher Scientific) and never 194 
grown for more than 15 passages. Cells were co-transfected with pMDG-VSV.G, 195 
pCMVdR8.74D64V, and either the Lenti-CaMKII-EKC or Lenti-CaMKII-GFP transfer plasmids. 196 
The mass ratio of envelope to packaging to transfer plasmids was 1 : 2.5 : 1.5. Transfections 197 
were performed according to the manufacturer’s instructions using Lipofectamine® 2000 198 
(Thermo Fisher Scientific). The transfection medium was replaced after 18 hours. Two 199 
media harvests were collected, at 40 hours and 60 hours after transfection. Harvested media 200 
were pre-cleaned by centrifugation at 1000 rpm for 3 minutes at 4 qC and filtered through 201 
0.45 Pm micropores. Media were overlaid on a sucrose solution with the following 202 
composition (in mM): 50 Tris-HCl, 100 NaCl, 0.5 EDTA (pH 7.4, 10% w/v sucrose), and 203 
centrifuged at 20,000 rpm for 2 hours at 4 qC. Lentiviral pellets were resuspended in sterile 204 
phosphate buffered saline (PBS), aliquoted, snap-frozen and stored at −80 qC. Viral titre was 205 
approximated using the Lenti-X™ p24 rapid titer kit (Clontech). Each titration was performed 206 
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in triplicate with three separate aliquots. Estimated titers were 2.42 × 109 infectious units 207 
(IU)/ml (Lenti-CaMKII-EKC) and 4.26 × 109 IU/ml (Lenti-CaMKII-GFP). 208 
 209 
AAV synthesis 210 
The recombinant AAV2/9 (rAAV2/9) AAV-CaMKII-EKC vector was produced in HEK293T 211 
cells grown in Gibco® DMEM + GlutaMAX™ supplemented with 10% heat-inactivated foetal 212 
bovine serum and 1% penicillin/streptomycin, and maintained in a humidified 5% CO2 213 
atmosphere at 37 °C. Cells were co-transfected with the AAV2 inverted terminal repeat 214 
(ITR)-containing AAV-CaMKII-EKC transfer plasmid, a helper plasmid expressing AAV2 rep 215 
and AAV9 cap, and a third plasmid expressing the adenovirus helper functions (Streck et al., 216 
2006). Transfections were performed using polyethylenimine MAX (Polysciences Inc.) and a 217 
plasmid ratio of 1 : 1 : 3, respectively. Cells were harvested 72 hours after transfection, and 218 
lysed with three freeze-thaw cycles (-80 °C to 37 °C) combined with regular vortexing in lysis 219 
buffer (150 mM NaCl, 50 mM Tris-HCl, pH 8.5) and a final benzonase (Sigma) treatment at 220 
37 °C for 1 hour. The rAAV2/9 vector was purified from the lysate using iodixanol gradient 221 
ultracentrifugation. The lysate was overlaid on increasing concentrations (15%, 25%, 40% 222 
and 60%) of iodixanol (OptiPrep, Sigma) in ultracentrifuge tubes (Beckman Instruments), 223 
and centrifuged for 3 hours at 20,000 g in a SW 40 Ti rotor (Beckman Instruments). The 224 
rAAV2/9 vector was extracted from the 40% fraction with a 19-gauge needle, diluted in 225 
sterile PBS, sterilised by filtration through 0.22 μm micropores, and concentrated using 226 
Vivaspin 20 centrifugal concentrators (100,000 molecular weight cut off; Sartorius Stedim 227 
Biotech). The final concentrated vector was stored at -80 °C. Vector titer was measured via 228 
quantitative polymerase chain reaction (PCR) using the Applied Biosystem StepOnePlus™ 229 
Real-Time PCR System (Thermo Fisher Scientific). Serial dilutions of the AAV-CaMKII-EKC 230 
transfer plasmid (101 – 109 plasmid copies/μl) were used as a template to create a standard 231 
curve. The reaction mixture comprised 5 μl of iTaq™ Universal SYBR® Green Supermix 232 
(Bio-Rad), 1 μl of each of the forward (5’ – CAGCACGCCTTCAAGACC – 3’) and reverse (5’ 233 
– AAGACTTCCTCTGCCCTCAC – 3’) primers at a concentration of 100 nM, 2 μl of DNA 234 
from either the plasmid standard or final vector, and 1 μl of distilled water. The PCR protocol 235 
consisted of an initial denaturation step at 95 °C for 30 minutes, 40 cycles of denaturation at 236 
95 °C for 5 minutes, annealing at 58 °C for 15 minutes, and extension at 72 °C for 10 237 
minutes, and a final melt curve stage. The reaction was performed in duplicate using three 238 
different dilutions of the concentrated vector sample (1: 100, 1: 1,000 and 1: 10,000 in 239 
distilled water). The estimated titer was 8.3 x 1014 viral genomes per ml. The rAAV2/9 AAV-240 
CaMKII-GFP control vector was commercially synthesised by VectorBuilder using an AAV2 241 
ITR-containing transfer plasmid designed and constructed in-house. 242 
 243 
Surgical procedures 244 
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All experiments were performed in accordance with the United Kingdom Animals (Scientific 245 
Procedures) Act 1986. For the FNE model, adult male rats (Sprague Dawley; 300-400g) 246 
were anesthetized and placed into a stereotaxic frame (Kopf). 15 ng of TeNT was injected 247 
into layer 5 of the right visual cortex in a final volume of 1.0 μl at a rate of 100 nl/min 248 
(coordinates: 3 mm lateral, 7 mm posterior of bregma, 1.0 mm deep from the pia). An ECoG 249 
transmitter (A3028E; Open Source Instruments, MA, USA) was implanted subcutaneously 250 
with a subdural intracranial recording electrode positioned above the injection site. A 251 
reference electrode was implanted in the contralateral hemisphere. A cannula (Plastics One) 252 
was positioned above the injection site for delivery of lentiviral vectors 11 or 14 days later. 253 
Each rat received a maximum of 2.0 μl of lentivirus injected directly into the seizure focus. 254 
Animals injected with TeNT were housed separately in Faraday cages for the duration of the 255 
study. For the TLE model, status epilepticus (SE) was induced using kainic acid (KA) 256 
administered according to a previously described protocol (Hellier et al., 1998). Briefly, adult 257 
male rats (Sprague Dawley; 200-250g) were injected intraperitoneally with KA (Tocris 258 
Bioscience, Bristol, UK) dissolved in sterile 0.9% saline (10 mg/ml). Injections were 259 
administered hourly at a dose of 5 mg/kg until class III, IV, or V seizures were evoked 260 
(scored according to a modified Racine’s scale (Racine, 1972; Ben-Ari, 1985)). KA 261 
administration was halted when animals reached class V seizures (rearing with forelimb 262 
clonus and falling over) or when the total dose of KA reached 45 mg/kg. Animals were 263 
included in the study if there was continuous motor seizure activity for 2 hours following the 264 
final dose of KA. Ten to 12 weeks after the induction of SE, rats were implanted with ECoG 265 
transmitters and bilateral guide cannulae for access to the dorsal and ventral hippocampus. 266 
After 4 weeks of baseline ECoG recording, animals were injected via the guide cannulae 267 
with a total of 8.0 μl of either the AAV-CaMKII-EKC vector (10× dilution) or its titer-matched 268 
AAV-CaMKII-GFP control. Vectors were delivered bilaterally into the dorsal and ventral 269 
hippocampus (two injection sites in each hemisphere) using the following coordinates: for 270 
dorsal hippocampus, ±2.8 mm lateral, 3.2 mm posterior of bregma, 3.1 mm deep from the 271 
pia; for ventral hippocampus, ±4.2 mm lateral, 5.2 mm posterior of bregma, 4.5 mm deep 272 
from the pia. Injections were administered at a rate of 200 nl/min, and the needle was left in 273 
place for 5 minutes after each injection. 274 
 275 
ECoG acquisition and analysis 276 
ECoG was recorded continuously for up to 6 weeks in the Lenti-CMV-KCNA1 pilot study and 277 
Lenti-CaMKII-EKC trial, and 13 weeks in the AAV-CaMKII-EKC trial. Data were acquired 278 
using A3028E implantable transmitters (0.3 – 160 Hz, 512 samples/s) and ancillary receivers 279 
and software (Open Source Instruments, Inc.). For the Lenti-CMV-KCNA1 pilot study and 280 
Lenti-CaMKII-EKC trial, spontaneous seizures were detected from chronic recordings as 281 
previously described (Chang et al., 2018; Lieb et al., 2018). For the AAV-CaMKII-EKC trial, 282 
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seizure detection was performed using semi-automated supervised learning 283 
(https://github.com/jcornford/pyecog). Briefly, a library of seizures was first created from 284 
events validated by visual inspection of ECoG traces (and video recordings where available). 285 
Library seizures were then divided into short epochs of 5 seconds, and random forest 286 
discriminative classification models trained to distinguish between epochs extracted from 287 
seizure or baseline periods. In order to facilitate classification, the discriminative models 288 
were trained using features extracted from each epoch, such as power in frequency bands 289 
and line-length. Discriminative model predictions of consecutive epochs were combined by 290 
treating the predictions as a sequence of observations generated by a hidden Markov model 291 
and applying the forward-backward algorithm. To parameterise the hidden Markov model, 292 
emission probabilities were calculated from classifier predictions and manual annotations 293 
were treated as hidden states. In all trials, recordings algorithmically classified as seizure 294 
activity were verified by visual inspection. 295 
 296 
Immunohistochemistry 297 
One week after injection of the Lenti-CaMKII-EKC vector, rats were terminally anesthetized 298 
with sodium pentobarbital (Euthatal; Merial) and transcardially perfused with cold (4 qC) 299 
heparinized PBS (80 mg/L heparin sodium salt; Sigma) followed by 4% paraformaldehyde 300 
(PFA) in PBS (Santa Cruz Biotechnology). Brains were removed and post-fixed in 4% PFA 301 
at 4 qC for a further 24 hours. After washing in PBS, brains were sliced into 70 Pm coronal 302 
sections using a vibrating microtome (Leica) and stored free-floating at 4 qC in PBS plus 303 
0.02% sodium azide (Sigma). For antibody staining, slices were permeabilized for 20 304 
minutes in PBS plus 0.3% Triton X-100 (Sigma) before blocking for 1 hour in PBS plus 0.3% 305 
Triton X-100, 1% bovine serum albumin (Sigma) and 4% goat serum (Sigma). Slices were 306 
incubated overnight at 4 qC in PBS plus 0.3% Triton X-100 and a rabbit anti-NeuN (diluted 307 
1:750; ab177487; Abcam), mouse anti-GFAP (diluted 1:500; MAB3402; Merck Millipore) or 308 
mouse anti-GAD67 (diluted 1:500; MAB5406; Merck Millipore) primary antibody. After three 309 
10 minute washes in PBS, slices were incubated at room temperature for 3 hours in PBS 310 
plus the relevant Alexa Fluor® 594-conjugated secondary antibody (goat anti-rabbit (A-311 
11037; Thermo Fisher Scientific) or goat anti-mouse (A-11005; Thermo Fisher Scientific), 312 
both diluted 1:750). After a further three 10 minute washes in PBS, slices were mounted 313 
onto plain glass microscope slides (Thermo Fisher Scientific) using Vectashield® HardSet™ 314 
mounting medium (Vector Laboratories) and borosilicate glass coverslips (VWR). Bright-field 315 
and fluorescence images were acquired using one of two microscopes: an Axio Imager A1 316 
fluorescence microscope (Axiovision LE software) equipped with 2.5×, 10× and 40× EC 317 
Plan-Neofluar non-immersion objectives, or an inverted LSM 710 confocal laser scanning 318 
microscope (ZEN 2009 software) equipped with 40× and 63× EC Plan-Neofluar oil-319 
immersion objectives (all Zeiss). For the confocal microscope, dscGFP and Alexa Fluor® 320 
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594 were excited with the 488 nm and 561 nm lines of an argon or diode pumped solid state 321 
(DPSS) laser, respectively. All image processing was performed using ImageJ software. 322 
Composite images were assembled using the MosaicJ ImageJ plugin. 323 
 324 
Experimental Design and Statistical Analysis 325 
Data from the Lenti-CMV-KCNA1 pilot study were used to determine sample sizes for the 326 
EKC trials. We estimated that the maximal weekly seizure frequency would double from 327 
baseline, and we wished to detect with 80% power a 40% reduction from this maximum at p 328 
< 0.05. Given a mean baseline weekly seizure frequency of 5 or above, a modification of 329 
Lehr’s formula (Lehr, 1992) for the Poisson distribution suggested 7 – 8 animals per group 330 
would be sufficient to detect a reduction in seizure frequency from 10 to 6 per week. Our 331 
modified Lehr’s formula is given by the following equation: 332 
 333 




where n is the size of each sample (treatment group), λ1 the mean weekly seizure frequency 335 
before treatment, and λ2 the mean weekly seizure frequency after treatment. 336 
 337 
Seizure counts in the baseline periods preceding treatment were compared using a two-338 
tailed Mann Whitney U test. The effects of treatment on normalized seizure frequency (Fig. 339 
1E, Fig. 3B and Fig. 4E) were analysed using a generalized log-linear mixed model with 340 
random effect of animal (autoregressive covariance) and fixed effects of treatment group, 341 
week, and the interaction between treatment group and week. The effects of treatment on 342 
overall seizure burden (Fig. 3D and Fig. 4F) and seizure clustering were analysed using a 343 
two-tailed Mann Whitney U test for the Lenti-CaMKII-EKC trial, and a two-tailed independent 344 
samples t-test for the AAV-CaMKII-EKC trial. The effects of treatment on seizure duration 345 
(Fig. 3E and Fig. 4G) were analysed using a two-way repeated-measured ANOVA with 346 
factors of time point (pre-treatment or post-treatment) and treatment group. Current densities 347 
at +20 mV (Fig. 2Bii) were compared using a Welch’s one-way ANOVA followed by Games-348 





A pilot study shows that KCNA1 gene therapy suppresses spontaneous seizures in a 352 
visual cortex epilepsy model 353 
We first asked whether the CMV-driven KCNA1 lentivector (Lenti-CMV-KCNA1) used 354 
previously in a model of EPC (Wykes et al., 2012) was also effective in a neocortical 355 
epilepsy model characterized by discrete seizures (Fig. 1A). Epilepsy was induced in adult 356 
rats with a single injection of TeNT into the primary visual cortex. Seizures in this model 357 
typically last between 50 and 200 s, are accompanied by unilateral, bilateral or generalized 358 
convulsions, and evolve over several weeks before fading (Chang et al., 2018; Lieb et al., 359 
2018). To monitor local electrographic activity, a wireless ECoG transmitter was implanted 360 
with a subdural intracranial recording electrode positioned above the injection site. Two 361 
weeks after TeNT administration, following the establishment of epilepsy, animals were 362 
randomized into two groups and injected via a pre-implanted cannula with either the Lenti-363 
CMV-KCNA1 vector or a Lenti-CMV-GFP control vector expressing only green fluorescent 364 
protein (GFP). Injections were delivered directly into the seizure focus and followed by a 365 
further 4 weeks of ECoG recording (Fig. 1B).  366 
 367 
The Lenti-CMV-KCNA1 lentivector transduced neurons within a narrow column of the cortex 368 
(Fig. 1C). As is typical of this model (Chang et al., 2018; Lieb et al., 2018), the total number 369 
of seizures experienced by each animal over the 6 weeks of recording was highly variable 370 
(Fig. 1D). Consequently, to compare seizure frequency between the two treatment groups 371 
the numbers of seizures experienced each week were normalized to the number 372 
experienced in the week preceding treatment (week −1, or baseline (Bl) week). Despite the 373 
small sample size (six treated vs. five controls), the Lenti-CMV-KCNA1 vector significantly 374 
reduced normalized seizure frequency compared to controls in the weeks following 375 
treatment (generalized log-linear mixed model on weeks 0 – 3, treatment group*week 376 
interaction effect: F(1,40) = 4.851, p = 0.033; Fig. 1E). The therapeutic effect emerged 377 
rapidly; plots of normalized cumulative daily seizure frequency for the two groups diverged 378 
within 3 days of lentivector injection, consistent with rapid transgene expression (Fig. 1F). 379 
 380 
This pilot study strongly suggests that KCNA1 gene therapy can suppress spontaneous 381 
discrete neocortical seizures. However, the Lenti-CMV-KCNA1 vector tested is poorly suited 382 
for clinical translation. We therefore set out to develop an optimized lentivector with 383 
improved safety and efficacy.  384 
 385 




The transfer plasmid used to synthesize the optimized lentivector differed from the original 388 
Lenti-CMV-KCNA1 construct in several ways (Fig. 2A). The non-cell-type specific CMV 389 
promoter was replaced with a 1.3 kb human CAMK2A promoter to bias expression to 390 
excitatory neurons (Dittgen et al., 2004; Yaguchi et al., 2013). The KCNA1 gene was codon-391 
optimized for expression in human cells, and mutated to introduce an I400V amino acid 392 
substitution normally generated by RNA editing. This substitution elicits a 20-fold increase in 393 
the rate at which Kv1.1 channels recover from inactivation (Bhalla et al., 2004). For pre-394 
clinical evaluation, the coding sequence of a short-lived dscGFP reporter was linked to the 395 
EKC gene by a T2A element, which permits dual peptide expression from a single promoter. 396 
To ensure that the EKC construct could produce functional Kv1.1 channels, we performed 397 
whole-cell patch clamp recordings in transfected Neuro-2a cells, a line selected for its high 398 
Camk2a promoter activity. Robust non-inactivating Kv1.1 currents were recorded in cells 399 
transfected with the EKC plasmid (Fig. 2B). 400 
 401 
The EKC transfer plasmid was packaged into a non-integrating lentiviral vector (Yáñez-402 
Muñoz et al., 2006; Rahim et al., 2009). When injected into the rat visual cortex, this Lenti-403 
CaMKII-EKC vector drove strong, localized expression of the dscGFP reporter (Fig. 2C). 404 
Imaging of sequential brain slices yielded an estimated transduction volume of 405 
approximately 0.074 mm3 (data not shown). Immunohistochemistry revealed no visible 406 
overlap between dscGFP expression and glial fibrillary acidic protein (GFAP) staining (0/512 407 
dscGFP+ cells stained for GFAP, n = 3 animals; Fig. 2Di). In contrast, all dscGFP+ cells 408 
stained positively for the neuronal marker NeuN (714/714, n = 3 animals; Fig. 2Dii). These 409 
data indicate that transgene expression from the EKC lentivector is restricted to neurons. 410 
There was minimal overlap between dscGFP expression and staining for glutamic acid 411 
decarboxylase 67 (GAD67), an enzymatic marker for GABAergic neurons (3/603 dscGFP+ 412 
cells stained for GAD67, n = 3 animals; Fig. 2Diii). This suggests that EKC transgene 413 
expression is largely restricted to excitatory neurons. 414 
 415 
Lenti-CaMKII-EKC gene therapy reduces seizure frequency in a blinded, randomized 416 
pre-clinical trial 417 
To test the therapeutic efficacy of the Lenti-CaMKII-EKC vector, we designed a blinded, 418 
randomized, placebo-controlled pre-clinical trial, and selected normalized seizure frequency 419 
as the primary outcome measure. Eleven days after injection of TeNT into the visual cortex, 420 
26 rats were randomized into two groups and injected via a pre-implanted cannula with 421 
either the Lenti-CaMKII-EKC vector or its dscGFP-only Lenti-CaMKII-GFP control. ECoG 422 
recordings were continued for a further 4 weeks. The timeline was altered from that of the 423 
pilot study to treat after 11 days in order to capture the period when seizure activity is at its 424 




To minimize the confounding influence of animals that displayed a very low seizure 427 
frequency prior to treatment and were therefore unlikely to develop chronic seizures, 428 
subjects were excluded if they exhibited fewer than five seizures in the week preceding 429 
lentiviral delivery (the baseline week). This criterion, established before commencement of 430 
the final pre-clinical trial and applied before unblinding, led to the exclusion of eight animals 431 
(six EKC, two control). Of the remaining 18, all but one survived for the duration of recording. 432 
This rat (from the EKC group) was culled in the final week due to detachment of its 433 
headpiece. However, because the subject had already passed through the period of peak 434 
seizure activity, and in order to maximise the amount of data obtained from the study, this 435 
incomplete dataset was included in the overall analysis. Again, this decision was made 436 
before unblinding. 437 
 438 
There was no significant difference between the treatment groups in the number of seizures 439 
experienced in the baseline week (Lenti-CaMKII-GFP median = 11 (interquartile range (IQR) 440 
10 – 26), Lenti-CaMKII-EKC median = 10 (IQR 7.5 – 12); Mann Whitney U test, p = 0.185). 441 
Analysis of the primary outcome measure indicated that Lenti-CaMKII-EKC therapy robustly 442 
decreased normalized seizure frequency compared to controls in the weeks following 443 
treatment (generalized log-linear mixed model on weeks 0 – 3, treatment group*week 444 
interaction effect: F(1,67) = 40.137, p < 0.001; Fig. 3B). The size of the effect was larger 445 
than that observed in the pilot study, suggesting that the EKC gene is more effective than its 446 
wild-type KCNA1 counterpart at suppressing neuronal hyperexcitability. As in the pilot study, 447 
the reduction in seizure frequency lasted for the duration of recording, and the absolute 448 
effect size only decreased as seizures abated in the control group. Again, the therapeutic 449 
effect emerged rapidly, with plots of normalized cumulative daily seizure frequency for the 450 
two groups diverging 2 days after treatment (Fig. 3C). To determine the effect of Lenti-451 
CaMKII-EKC therapy on overall seizure burden, which is an important determinant of 452 
comorbidities and mortality in epilepsy (Trinka et al., 2013), we compared total post-453 
treatment seizure counts (normalized to baseline) between the two treatment groups. Lenti-454 
CaMKII-EKC therapy significantly reduced the overall seizure burden (Mann Whitney U test, 455 
p = 0.044; Fig. 3D). Lenti-CaMKII-EKC therapy had no significant effect on the duration of 456 
seizures that persisted after treatment (two-way repeated-measures ANOVA on average 457 
durations before and after treatment, treatment group*time point interaction effect: F(1,16) = 458 
2.640, p = 0.124; Fig. 3E).  459 
 460 
The visual cortex TeNT model of FNE exhibits pronounced seizure clustering (Chang et al., 461 
2018; Lieb et al., 2018), which is also common in human epilepsies (Karoly et al., 2016) and 462 
has been reported to correlate with poor clinical outcome and quality of life, and even 463 
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mortality (Sillanpää and Schmidt, 2008). We therefore asked if Lenti-CaMKII-EKC therapy 464 
influenced seizure clustering in the current study. The degree of clustering was quantified by 465 
calculating the post-treatment Fano factor – the ratio of the mean number of seizures to the 466 
variance – for control and EKC-treated animals. This revealed a non-significant trend for a 467 
lower degree of clustering, as indicated by the Fano factor, in EKC-treated animals 468 
compared to controls (Lenti-CaMKII-GFP median = 4.58 (IQR 1.91 – 14.57), Lenti-CaMKII-469 
EKC median = 2.06 (IQR 0.86 – 3.25); Mann Whitney U test, p = 0.073).  470 
 471 
AAV-CaMKII-EKC gene therapy suppresses seizures in a temporal lobe epilepsy 472 
model  473 
To determine whether the efficacy of EKC gene therapy was specific to lentiviral treatment of 474 
FNE, we performed an additional randomized, blinded trial in a model of TLE induced by 475 
systemic KA injection. Because the seizure focus is more diffuse in this model, we delivered 476 
the EKC gene (again under the CAMK2A promoter) bilaterally to the hippocampi using a 477 
rAAV2/9 vector. Rats were implanted with wireless ECoG transmitters 10 – 12 weeks after 478 
the induction of SE by intraperitoneal KA. After recording baseline seizure activity for 4 479 
weeks, 16 epileptic animals were randomized into two groups for injection via pre-implanted 480 
cannulae with either an AAV-CaMKII-EKC vector (Fig. 4A) or a dscGFP-only AAV-CaMKII-481 
GFP control. ECoG recordings were continued for a further 9 weeks (Fig. 4B). 482 
 483 
The AAV-CaMKII-EKC vector drove strong, widespread expression of the dscGFP reporter 484 
throughout the hippocampus (Fig. 4C). As for the visual cortex model of FNE, seizure counts 485 
in the TLE model were highly variable (Fig. 4D), so comparisons between the two treatment 486 
groups were made after normalizing weekly counts to the mean number of seizures 487 
experienced per week in the baseline period. The analysis was performed blind to treatment. 488 
There was no significant difference between the groups in the number of seizures 489 
experienced during this baseline period (AAV-CaMKII-GFP median = 34 (IQR 15 – 62.75), 490 
AAV-CaMKII-EKC median = 41.5 (IQR 22.25 – 55.5); Mann Whitney U test, p = 0.521). 491 
AAV-CaMKII-EKC therapy robustly decreased normalized seizure frequency compared to 492 
controls in the weeks following treatment (generalized log-linear mixed model on weeks 0 – 493 
8, treatment group*week interaction effect: F(1,126) = 6.331, p = 0.013; Fig. 4E). AAV-494 
CaMKII-EKC therapy also led to a significant reduction in the overall seizure burden 495 
(independent samples t-test, t(14) = 3.54, p = 0.003; Fig. 4F). In contrast to the visual cortex 496 
TeNT study above, the average seizure duration decreased after treatment (two-way 497 
repeated-measures ANOVA on average durations before and after treatment, treatment 498 
group*time point interaction effect: F(1,14) = 11.20, p = 0.005; Fig. 4G). Seizure clustering 499 
was unaffected (independent samples t-test comparing post-treatment Fano factors, t(14) = 500 





The present study shows EKC gene therapy to be effective in models of both FNE and TLE, 504 
providing strong justification for further clinical development.   505 
 506 
Early studies of gene therapy for epilepsy focused on acutely precipitated seizures, which 507 
often translate poorly (Galanopoulou et al., 2012). More recent strategies, mainly involving 508 
AAVs in models of TLE, have shown that the development of seizures after an epileptogenic 509 
insult (epileptogenesis) can be attenuated (Haberman et al., 2003; Richichi et al., 2004; Lin 510 
et al., 2006; McCown, 2006; Kanter-Schlifke et al., 2007; Noè et al., 2008; Bovolenta et al., 511 
2010; Woldbye et al., 2010; Nikitidou et al., 2014). Here we show, in models of both TLE and 512 
FNE using both AAV and lentiviral vectors, that potassium channel gene therapy can 513 
suppress spontaneous recurrent seizure activity that is already established. 514 
 515 
We have previously shown that overexpression of Kv1.1 can reduce the frequency of brief 516 
(less than 1 second), high-frequency epileptiform discharges in a motor cortex TeNT model 517 
of EPC (Wykes et al., 2012). However, that study did not investigate whether Kv1.1 518 
overexpression could inhibit discrete seizures lasting 1 – 2 minutes, more typical of common 519 
forms of focal epilepsy. We show here, in three independent trials, that Kv1.1 520 
overexpression is indeed sufficient to reduce the frequency of discrete, long-lasting seizures. 521 
In vitro studies have demonstrated that Kv1.1 overexpression reduces both intrinsic neuronal 522 
excitability and glutamate release from transduced pyramidal neurons (Heeroma et al., 2009; 523 
Wykes et al., 2012), which may provide a mechanism for limiting seizure initiation. 524 
Importantly, both these effects on neuronal properties are graded, with neither neuronal 525 
excitability nor neurotransmitter release completely abolished. 526 
 527 
Interestingly, AAV-CaMKII-EKC therapy in the TLE model reduced both the frequency and 528 
the duration of seizures, while Lenti-CaMKII-EKC therapy in the FNE model reduced only 529 
seizure frequency. This difference may be explained by the spread of AAV and lentiviral 530 
vectors through the brain parenchyma in relation to seizure-generating networks. In the FNE 531 
model, the motor convulsions that accompany the majority of seizures suggest that seizure 532 
initiation is rapidly followed by propagation to brain areas outside the TeNT-injected primary 533 
focus (Chang et al., 2018; Lieb et al., 2018). Because Lenti-CaMKII-EKC remained confined 534 
to the injection site, such propagation would leave EKC channels unable to influence the 535 
termination, and thus duration, of seizure activity. Conversely, the fact that bilateral 536 
hippocampal AAV-CaMKII-EKC treatment reduces seizure duration in the TLE model 537 





Lentiviral gene therapy approaches are becoming more common in CNS disorders, and 541 
have shown good safety and tolerability even in extended trials (Palfi et al., 2014). However, 542 
a potential safety concern with retroviral vectors is the inherent risk of insertional 543 
mutagenesis (Hacein-Bey-Abina et al., 2003; Baum et al., 2004). This risk can be minimized 544 
by rendering vectors integration-deficient. The popularity of non-integrating lentiviruses for 545 
therapeutic gene transfer is growing, and the vectors have already demonstrated pre-clinical 546 
efficacy in the treatment of degenerative retinal disease and haemophilia B (Yáñez-Muñoz et 547 
al., 2006; Suwanmanee et al., 2014). The non-integrating EKC lentivirus described here 548 
drove strong, localized transgene expression after direct injection into the rat neocortex, and 549 
rapidly and persistently suppressed focal seizure activity. This supports the use of 550 
integration-deficient vectors as safe, effective delivery tools for gene therapy of neurological 551 
disease. 552 
 553 
In the case of epilepsy, an additional safety concern is the possibility of potassium channel 554 
overexpression in interneurons, which could aggravate seizure activity by exacerbating 555 
rather than attenuating local excitability. To mitigate this risk we have used a human 556 
CAMK2A promoter that in rats led to very little expression in GABAergic cells. Promoter 557 
specificity can differ between species (Yaguchi et al., 2013; Lerchner et al., 2014), and the 558 
specificity of the human CAMK2A promoter for excitatory glutamatergic neurons will 559 
ultimately need to be validated in the human brain. Evidently, if EKC gene therapy is to 560 
progress to the clinic, such validation will need to be performed in the absence of a 561 
fluorescent reporter. 562 
 563 
Because the role of potassium channels, including Kv1.1, in regulating neuronal excitability 564 
is conserved across a broad range of neurons, potassium channel overexpression may hold 565 
therapeutic promise in the treatment of other diseases characterized by neuronal 566 
hyperexcitability. There is currently an unmet clinical need for new treatments of chronic 567 
pain, and a variety of gene therapy approaches aimed at reducing the excitability of dorsal 568 
root ganglion neurons have already demonstrated pre-clinical efficacy (Snowball and 569 
Schorge, 2015). Other disorders such as Parkinson’s disease are associated with excessive 570 
activity in specific groups of neurons (Lobb, 2014), and could be candidates for treatment 571 
with an appropriate combination of potassium channel subtype and cell-type-specific 572 
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Figure legends 748 
 749 
Figure 1: A pilot study suggests KCNA1 gene therapy can suppress genuine discrete 750 
seizures in the visual cortex TeNT model of FNE. A. Representative occipital lobe seizure 751 
experienced by an adult rat 2 weeks after injection of TeNT into the primary visual cortex. 752 
Expanded sections are taken at the times indicated. B. Timeline highlighting key 753 
experimental milestones. C. Neuronal transduction with the Lenti-CMV-KCNA1 vector was 754 
restricted to a narrow column of cortex surrounding the site of injection. D. Number of 755 
seizures (per week) experienced by animals injected with the Lenti-CMV-KCNA1 vector 756 
(blues; n = 6) or its GFP-only Lenti-CMV-GFP control (reds; n = 5). Data are plotted on a 757 
logarithmic scale after incrementing each seizure count by 1 to avoid zero values. E. 758 
Normalized seizure frequency (per week) for the two groups. The numbers of seizures 759 
experienced each week were normalized to the number experienced by each animal in the 760 
week preceding treatment (week Bl). F. Normalized cumulative seizure frequency (per day). 761 
Cumulative seizure counts were also normalized to the total number experienced in week Bl. 762 
Data in panels E and F are presented as mean ± the standard error of the mean (SEM).  763 
 764 
Figure 2: Design and characterization of an EKC gene therapy optimized for clinical 765 
translation. A. Transfer plasmid maps for the Lenti-CMV-KCNA1 pilot vector (i), the 766 
optimized Lenti-CaMKII-EKC vector (ii), and its Lenti-CaMKII-GFP control (iii). Abbreviations: 767 
RSV – Rous sarcoma virus promoter; LTR – long terminal repeat; HIV-1 Ψ – HIV-1 768 
packaging signal; RRE – Rev response element; cPPT/CTS – central polypurine tract and 769 
central termination sequence; EF1α – elongation factor 1 α promoter; WPRE – woodchuck 770 
hepatitis virus post-transcriptional regulatory element. B. Heterologous expression of 771 
functional Kv1.1 channels from the optimized Lenti-CaMKII-EKC transfer plasmid. (i): 772 
Representative current-time trace from a Neuro-2a cell transfected with the Lenti-CaMKII-773 
EKC transfer plasmid. (ii): Plot of mean current density against voltage for cells transfected 774 
with the Lenti-CaMKII-EKC transfer plasmid (Kv; n=13), cells transfected with the Lenti-775 
CaMKII-GFP control plasmid (G; n=8), and untransfected controls (UT; n=10). Inset: 776 
histogram showing differences in current density between the three groups during the 777 
voltage step to +20 mV (Kv vs. UT: p=0.0013; Kv vs. G: p=0.0012; UT vs. G: p=0.82; ns = 778 
not significant; Welch’s one-way ANOVA with Games-Howell post-hoc tests). (iii): Plot of 779 
mean normalized conductance against voltage for cells transfected with the Lenti-CaMKII-780 
EKC transfer plasmid. Data are fit with a single Boltzmann function. The V0.5 of −28.2 mV is 781 
similar to values obtained from HEK293 cells transfected with CMV-driven, wild-type KCNA1 782 
(−32.8 ± 0.9 mV) (Tomlinson et al., 2013). All error bars represent SEM. C. Bright-field and 783 
fluorescence images of a brain slice from a rat injected in the left visual cortex with 1.25 μl 784 
(a3.0 x 106 IU) of the Lenti-CaMKII-EKC vector. The pattern of transduction is similar to that 785 
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observed with the Lenti-CMV-KCNA1 vector. D. Immunohistochemical assessment of the 786 
cell type specificity of EKC expression. (i): There was no overlap between transduced 787 
neurons expressing dscGFP and astrocytes stained for GFAP. (ii): There was 100% overlap 788 
between dscGFP+ cells and neurons stained for NeuN. (iii): Minimal overlap was observed 789 
between dscGFP+ cells and inhibitory interneurons stained for GAD67. 790 
 791 
Figure 3: EKC gene therapy robustly reduces seizure frequency in a blinded, 792 
randomized, placebo-controlled pre-clinical trial. A. Timeline highlighting key 793 
experimental milestones. Note the injection of lentiviral vectors 11 rather than 14 days after 794 
TeNT delivery. B. Normalized seizure frequency (per week) for animals treated with the 795 
Lenti-CaMKII-EKC lentivector (blue; n = 7/6) or its Lenti-CaMKII-GFP control (red; n = 11). 796 
C. Normalized cumulative seizure frequency (per day). D. Normalized post-treatment seizure 797 
totals. E. Individual and overall average seizure durations before (left) and after (right) 798 
treatment. Data in panels B-E are presented as mean ± SEM. 799 
 800 
Figure 4: EKC gene therapy is effective in a model of TLE. A. Transfer plasmid map for 801 
the AAV-CaMKII-EKC vector. Abbreviations: hGH poly(A) signal – human growth hormone 802 
polyadenylation signal. B. Timeline highlighting key experimental milestones. C. 803 
Representative fluorescence image of a brain slice from a rat injected in the bilateral 804 
hippocampus with 8.0 μl of undiluted AAV-CaMKII-EKC vector. D. Number of seizures (per 805 
week) experienced by animals injected with the AAV-CaMKII-EKC vector (blues; n = 8) or its 806 
AAV-CaMKII-GFP control (reds; n = 8). Data are plotted on a logarithmic scale after 807 
incrementing each seizure count by 1 to avoid zero values. E. Normalized seizure frequency 808 
(per week) for the two groups. F. Normalized post-treatment seizure totals. G. Individual and 809 
overall average seizure durations before (left) and after (right) treatment. Data in panels E-G 810 
are presented as mean ± SEM. 811 
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